Ingelheim, Germany – May 22, 2026
Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved HERNEXEOS® (zongertinib tablets) as the first targeted oral therapy for adult patients with HER2-mutant advanced non-small cell lung cancer (NSCLC) at initial diagnosis. The landmark approval positions HERNEXEOS as a major advancement in precision oncology for lung cancer patients in China and reinforces the growing global momentum behind targeted therapies for genetically driven cancers. The approval follows the recent accelerated approval of the therapy in the United States and marks another significant milestone for Boehringer Ingelheim’s oncology expansion strategy.
China Approval Expands First-Line Targeted Treatment Options
The NMPA approval allows HERNEXEOS to be used as a monotherapy for adult patients with unresectable, locally advanced, or metastatic NSCLC whose tumors contain activating HER2 (ERBB2) tyrosine kinase domain mutations. The conditional authorization was granted based on results from the Phase Ib Beamion LUNG-1 trial, which demonstrated strong clinical activity in treatment-naïve patients with HER2-mutant lung cancer.
According to trial findings, HERNEXEOS achieved an impressive 75.7% objective response rate (ORR) among newly diagnosed patients. Notably, 10.8% of patients experienced complete response, while 64.9% achieved partial response, highlighting the therapy’s substantial anti-tumor activity. Researchers also reported a median duration of response of 15.2 months, indicating durable clinical benefit in a patient population with historically limited treatment options.
The safety profile was also encouraging, with most treatment-related adverse events classified as low-grade. In the pooled safety analysis involving 177 patients, only 9% required dose reductions and 6% discontinued treatment due to adverse events. The clinical data were presented at the European Lung Cancer Congress 2026 and published in The New England Journal of Medicine, strengthening confidence in the therapy’s global clinical value.
Advertisement
Precision Oncology Gains Momentum in HER2-Mutant Lung Cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide, and the disease burden continues to rise sharply in China. Non-small cell lung cancer accounts for the majority of lung cancer cases, with many patients diagnosed at advanced stages where survival outcomes remain poor. HER2 mutations are estimated to drive up to 4% of lung cancer cases, creating a critical need for highly targeted therapeutic approaches.
Medical experts noted that patients with HER2-mutant NSCLC have historically faced significant diagnostic and therapeutic challenges due to the lack of effective targeted treatments specifically designed for this genetic subtype. The approval of HERNEXEOS therefore represents a major advancement in delivering more personalized and precise lung cancer care.
HERNEXEOS is an irreversible tyrosine kinase inhibitor (TKI) engineered to selectively inhibit HER2 while sparing wild-type EGFR, helping reduce off-target toxicities commonly associated with other therapies. By directly targeting HER2-driven tumor signaling, the treatment aims to slow tumor growth while improving tolerability for patients requiring long-term therapy.
Boehringer Expands Global Oncology Pipeline
The latest approval strengthens Boehringer Ingelheim’s growing presence in oncology and underscores the company’s commitment to redefining standards of care in cancer treatment. Beyond China, HERNEXEOS has already secured approvals in the United States, Japan, and Hong Kong, making it the first orally administered targeted therapy approved for HER2-mutant advanced NSCLC in multiple major markets.
The company is also advancing a broader global clinical program for zongertinib across multiple stages of disease. The ongoing Phase III Beamion LUNG-2 study is evaluating the therapy as a first-line treatment for advanced HER2-mutant NSCLC, while Beamion LUNG-3 is exploring its use as an adjuvant therapy in early-stage resectable lung cancer.
Industry analysts believe the approval reflects the accelerating shift toward biomarker-driven precision oncology, where therapies are increasingly tailored to specific molecular mutations rather than broad tumor classifications. As demand for targeted cancer medicines continues to rise globally, Boehringer Ingelheim’s success with HERNEXEOS could significantly strengthen its long-term oncology portfolio and competitive position in the rapidly evolving lung cancer therapeutics market.
Source: Boehringer Ingelheim press release
